The WRAPSODY CIE is designed to help physicians prolong functional vascular access in hemodialysis patients.Approval was supported by superior 12-month target lesion primary patency (70.1%) and access circuit primary patency (58.1%) in the randomized arm of the trial. SOUTH JORDAN, Utah, May 06, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that the Wrapsody Cell-Impermeable Endoprosthesis (CIE) received regulatory approval fro ...

Core Insights - The article compares Labcorp (LH) and Merit Medical (MMSI) to determine which stock offers better value for investors [1] Valuation Metrics - Labcorp has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while Merit Medical has a Zacks Rank of 4 (Sell) [3] - Labcorp's forward P/E ratio is 15.44, significantly lower than Merit Medical's forward P/E of 28.18 [5] - Labcorp has a PEG ratio of 1.57, while Merit Medical's PEG ratio is 2.74, suggesting Labcorp is expected to grow earnings at a more favorable rate [5] - Labcorp's P/B ratio is 2.50 compared to Merit Medical's P/B of 3.96, indicating Labcorp is more favorably valued against its book value [6] - Based on these metrics, Labcorp earns a Value grade of A, while Merit Medical receives a Value grade of D [6] Earnings Outlook - Labcorp is noted for its improving earnings outlook, which enhances its attractiveness as a value investment [7]

In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) achieved 60.2% target lesion primary patency (TLPP) at 12 months.SOUTH JORDAN, Utah, May 05, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced that the 12-month results from the single-arm cohort of the WAVE trial were presented at the annual Charing Cross Symposium held in London, England, on April 23, 2025, during the Vascular Access Mas ...

Merit Medical Systems, Inc. (MMSI) reported first-quarter 2025 adjusted earnings per share (EPS) of 86 cents, up 14.7% from the year-ago quarter. The bottom line surpassed the Zacks Consensus Estimate by 14.7%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)GAAP EPS for the quarter was 49 cents, down by a penny year over year.MMSI’s Revenue DetailsRevenues grossed $355.4 million in the reported quarter, up 9.8% year over year on a reported basis. The metric topped the Zacks Consens ...

Merit Medical Systems (MMSI) Q1 2025 Earnings Call April 25, 2025 02:35 AM ET Company Participants Fred Lampropoulos - Founder, CEO & ChairmanBrian Lloyd - Chief Legal Officer and Corporate SecretaryRaul Parra - CFO & TreasurerSimran Modi - Vice PresidentMichael Petusky - Managing DirectorJon Young - DirectorJayson Bedford - Managing Director, Equity Research Conference Call Participants Jason Bednar - Senior Research AnalystSteve Lichtman - Managing Director, Senior Research AnalystRobbie Marcus - AnalystC ...

For the quarter ended March 2025, Merit Medical (MMSI) reported revenue of $355.35 million, up 9.8% over the same period last year. EPS came in at $0.86, compared to $0.77 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $352.33 million, representing a surprise of +0.86%. The company delivered an EPS surprise of +14.67%, with the consensus EPS estimate being $0.75.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Str ...

Merit Medical (MMSI) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.77 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 14.67%. A quarter ago, it was expected that this maker of disposable medical devices would post earnings of $0.83 per share when it actually produced earnings of $0.93, delivering a surprise of 12.05%.Over the last f ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . (Exact name of registrant as specified in its charter) Utah 87-0447695 (State or other jurisdiction of incorporation or organization) (IRS Employe ...

Contacts: PR/Media Inquiries: Sarah Comstock Merit Medical +1-801-432-2864 +1-443-213-0509 Investor Inquiries: Mike Piccinino, CFA, IRC ICR Healthcare sarah.comstock@merit.com mike.piccinino@icrhealthcare.com FOR IMMEDIATE RELEASE MERIT MEDICAL REPORTS FIRST QUARTER 2025 RESULTS AND UPDATES FULL-YEAR GUIDANCE First Quarter Highlights† Exhibit 99.1 † Comparisons above are calculated for the current quarter compared with the first quarter of 2024, unless otherwise specified. Amounts stated in this release are ...

Core Insights - Merit Medical Systems, Inc. reported a revenue of $355.4 million for Q1 2025, reflecting a 9.8% increase compared to Q1 2024 [4][6] - The company achieved a constant currency revenue growth of 10.9% and an organic constant currency revenue increase of 6.0% year-over-year [4][6] - Non-GAAP earnings per share (EPS) rose by 14.8% to $0.86, while GAAP EPS increased by 2.0% to $0.49 [6][9] Financial Performance - The GAAP operating margin improved to 11.5% from 11.1% in the prior year, while the non-GAAP operating margin increased to 19.3% from 17.0% [6][8] - Free cash flow generation was reported at $19.5 million, down 20.5% compared to the previous year [6] - The company’s GAAP net income for Q1 2025 was $30.1 million, compared to $28.2 million in Q1 2024 [9] Revenue Breakdown - Revenue by segment showed significant growth in the Cardiovascular segment, with a 10.6% increase in Cardiac Intervention and a 20.5% increase in OEM [5] - The Endoscopy segment also saw substantial growth, with revenue increasing by 64.2% [7] - Total revenue for the Cardiovascular segment was $338.7 million, up 8.1% year-over-year [5] Guidance and Outlook - The company reaffirmed its total revenue guidance for 2025, projecting revenues between $1.470 billion and $1.490 billion, representing an 8% to 10% year-over-year increase [11] - Non-GAAP EPS guidance was updated to reflect stronger-than-expected Q1 results, now projected between $3.29 and $3.42 [11] - The company anticipates continued stable constant currency growth despite potential impacts from trade policies [5][11] Balance Sheet Highlights - As of March 31, 2025, Merit had cash and cash equivalents of $395.5 million, an increase from $376.7 million at the end of 2024 [10] - Total debt obligations remained stable at $747.5 million [10] - The company had an available borrowing capacity of approximately $697 million [10]